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randomised controlled trial of a group-based
fatigue management programme (FACETS) for
people with multiple sclerosis
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Angela Davies Smith3, Roger Baker1, Kathleen T Galvin5 and Charles Hillier4Abstract
Background: Fatigue is one of the most common and debilitating symptoms of multiple sclerosis (MS). The aim
was to evaluate the effectiveness at 1-year follow-up of a manualised group-based programme (‘FACETS’) for
managing MS-fatigue.
Methods: One-year follow-up of a pragmatic multi-centre randomised controlled trial. People with MS and significant
fatigue were randomised to FACETS plus current local practice (FACETS) or current local practice alone (CLP), using
concealed computer-generated randomisation. Participant blinding was not possible. Primary outcome measures were
fatigue severity (Global Fatigue Severity subscale of the Fatigue Assessment Instrument), self-efficacy (MS-Fatigue
Self-Efficacy) and disease-specific quality of life (MS Impact Scale).
Results: Between May 2008 and November 2009, 164 participants were randomised. Primary outcome data were
available at 1 year for 131 (80%). The benefits demonstrated at 4-months in the FACETS arm for fatigue severity
and self-efficacy largely persisted, with a slight reduction in standardised effect sizes (SES) (−0.29, p = 0.06 and
0.34, p = 0.09, respectively). There was a significant difference on the MS Impact Scale favouring FACETS that had
not been present at 4-months (SES −0.24, p = 0.046). No adverse events were reported.
Conclusions: Improvements in fatigue severity and self-efficacy at 4-months follow-up following attendance of
FACETS were mostly sustained at 1 year with additional improvements in MS impact. The FACETS programme
provides modest long-term benefits to people with MS-fatigue.
Trial registration: ISRCTN76517470
Keywords: Randomised controlled trial, Multiple sclerosis, Fatigue, Intervention, Energy effectiveness, Cognitive
behavioural, GroupBackground
Fatigue is one of the most common and debilitating
symptoms of MS [1-5]. We have developed a non-
pharmacological group-based fatigue management prog-
ramme for people with MS called FACETS (Fatigue:
Applying Cognitive behavioural and Energy effectiveness
Techniques to lifeStyle) [6]. One of the criticisms of non-* Correspondence: saraht@bournemouth.ac.uk
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unless otherwise stated.pharmacological trials is that they often do not include
any long term follow-up. This paper reports on one year
follow-up data obtained from a pragmatic three-centre
trial of FACETS [7].Methods
We carried out a pragmatic multi-centre randomised
controlled trial following the published protocol [8] in
which the full study design, inclusion and exclusion
criteria, trial arms, and plan of analysis are described
in detail. The main results are reported elsewhere [7].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Thomas et al. BMC Neurology 2014, 14:109 Page 2 of 6
http://www.biomedcentral.com/1471-2377/14/109Here we report the results from the 1 year self-reported
follow-up data.
Participants were recruited in three UK centres (Poole,
Bristol, Southampton/Portsmouth) from primary or sec-
ondary care, or via MS Society newsletters/websites.
Recruitment took place from May 2008 to November
2009. Ethical approval was obtained from the South
West-Central Bristol Research Ethics Committee (ref:
08/H0106/2). All participants provided written informed
consent before taking part.
The main inclusion criteria were: (1) clinically definite
MS diagnosis, (2) fatigue impacting on daily life (Fatigue
Severity Scale total score >4) [9] and (3) ambulatory. The
main exclusion criteria were: (1) having taken part in a
fatigue programme in the last year, (2) cognitive impair-
ments (3) a relapse in the previous 3 months or (4) having
started treatment with disease modifying or antidepressant
drugs within the previous 3 months. The full eligibility
criteria are described in the protocol [8].
Intervention (FACETS programme)
The manualised group-based FACETS programme is
described elsewhere [6] and is based upon a conceptual
framework integrating elements from cognitive behavioural,
social-cognitive, energy effectiveness, self-management
and self-efficacy theories. The aim of the intervention is to
help people with MS normalise their fatigue experiences,
learn helpful ways of thinking about fatigue and use avail-
able energy more effectively. The intervention consists of
six sessions (∼90 min duration) held weekly and facilitated
in groups of 6–12 by two health professionals with experi-
ence of working with people with MS and group-work
(such as occupational therapists, nurses or physiothera-
pists). Each session follows the same general format,
namely, facilitator-delivered presentations, flipchart dis-
cussions, group activities and homework. The facilitator
manual provides guidance on preparation and delivery,
detailed session content, notes and suggested timings,
and a checklist of facilitator objectives as well as sign-
posts to additional resources. Sessions are delivered via
PowerPoint; hence can be easily replicated. A companion
participant handbook, along with existing information
booklets, reinforces programme content.
FACETS was delivered in hotel meeting-room facilities,
with the exception of one centre, where it was held in
a rehabilitation hospital. Apart from one MS specialist
nurse, facilitators were either occupational therapists
or physiotherapists. Facilitators were trained to deliver
the intervention at 1-day workshops and psychological
advice and debriefing were available for facilitators
throughout the trial.
To increase external validity, no attempt was made in
the FACETS arm to restrict or control participants’ access
to current local practice or to standardise it acrosshealthcare settings or treatment arms. When we refer to
the FACETS arm, participants in this arm also received
current local practice.
Control group (Current Local Practice (CLP))
Participants randomised to this arm of the trial received
current local practice.
This could have ranged from general advice and infor-
mation provision about MS-fatigue to more detailed indi-
vidualised management advice from a variety of health
professionals. Inevitably, there will have been variations
in the exact composition of what was usually provided,
within and between centres, depending on local resources
and patient need. Collecting detailed information at an
individual level on the type and quantity of advice re-
ceived as part of current local practice was not deemed
feasible. However, this real world variation increases
applicability to a wider range of centres.
Outcomes
For those allocated to the FACETS arm outcomes were
measured 1 week (baseline) before the start of the FACETS
programme and 1 month (follow-up 1), 4 months (follow-
up 2) and 12 months (follow-up 3) after the final session.
Participants in the current local practice arm completed
outcome measures within an identical time frame. Data
from follow-up 1 and 2 have previously been reported [7].
In this paper we focus on reporting follow-up 3.
Primary outcomes were fatigue severity (Global Fatigue
Severity (GFS) subscale of the Fatigue Assessment Instru-
ment (FAI)), disease specific quality of life (Multiple Scler-
osis Impact Scale (MSIS-29, V.1)) and self-efficacy for
managing fatigue (Multiple Sclerosis - Fatigue Self-Efficacy
scale (MS-FSE)) [7,8].
Secondary outcomes included the Fatigue Symptom
Inventory (FSI), the Hospital Anxiety and Depression
Scale (HADS), the Medical Outcomes Short-Form Survey
(SF-36, V. 2), and subscales of the MSIS-29 (V.1) and the
FAI [7,8]. All outcomes collected at 12 months were self-
reported questionnaires and administered postally.
Sample size considerations
The sample size requirement was 146 participants with
follow-up data based on having 85% power to detect a
medium standardised effect size of 0.5 for the primary
outcome measures, using a two-sided 5% significance
level (see protocol for justification for this medium effect
size) [8]. As a variety of fatigue measures have been used
in other trials, we used standardised effect sizes to enable
comparisons between them.
Analysis
The main analysis was intention-to-treat but we also
conducted a per protocol analysis (excluding participants
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were analysed using IBM SPSS, V.18 and MLwiN 2.17.
Outcome measures were assumed to be interval-scaled
and the main analysis focused on absolute change in
outcomes at 1 year follow-up relative to baseline. Change
scores were compared between the groups using the inde-
pendent samples t-test with a two sided 5% significance
level, and summarised using mean differences (95% confi-
dence intervals (CIs)) and standardised effect sizes (SES).
As detailed in the protocol, additional pre-specified sup-
plementary analyses were undertaken. Here we report
results from a mixed model approach that includes
1 year and baseline measurements as repeated mea-
sures, incorporates clustering effects, and includes
pre-specified covariates (baseline for other primary
outcomes, age, gender, marital status, education level,
type of MS, time since diagnosis, level of disability,
and centre).Results
One year follow up data are available on 131 participants
(80%) (Figure 1). The distributions of descriptive statistics
for the trial sample are presented in Table 1.Follow-Up 3 (1 Year)  
Baseline  
 
Randomised
stratified by
Follow-up 3 (n=62/81*) 
*3 dropouts prior to follow-up 3 
(second condition diagnosed, n=1; personal reasons, n=2) 
 
 
Did not return outcome measures (n=15) 
Dropped out (personal reasons) (n=3) 
Dropped out (second condition diagnosed) (n = 1) 
 
 
 
Allocated to FACETS (n=84) 
 Received allocated intervention (at least 4 sessions) 
(n=72) 
 Did not receive any intervention (n=10) 
Changed mind (n=3); operation (n=1); unwell/relapse 
(n=2); work commitments  (n=3); ‘too much on’ ( n=1)  
 Withdrew from intervention after 1 session (n=2) 
Had reservations about group format (n=1); reason 
unknown (n=1) 
 
Missing baseline assessments (n=3) 
Participant information pack
Figure 1 Participant flow.Primary outcomes
The intention-to-treat analyses and results for the primary
outcome measures are shown in Table 2.
Results for fatigue severity and self-efficacy were similar
to those at 4 months with a slight reduction in standar-
dised effect size (SES) from −0.35 (p = 0.01) for fatigue
severity to −0.29 (p = 0.06) and from 0.36 (p = 0.048) for
fatigue self-efficacy to 0.34 (p = 0.09). There were sig-
nificantly greater improvements on the MSIS-29 for the
FACETS arm compared with the CLP arm (p = 0.046,
SES = −0.24) that were not evident at 4 months.
The per protocol analysis resulted in an increased SES for
the MSIS-29 (from −0.24 to −0.26 (p = 0.03)) and for the
MS-FSE (from 0.34 to 0.39 (p = 0.046)). The SES for the
GFS subscale was reduced from −0.29 to −0.25 (p = 0.10).
Participants in the FACETS arm were 1.5 times more
likely (31% (19/62) versus 20% (14/69)) to have a clinically
important improvement on the GFS (defined as an individ-
ual reduction of ≥ 0.5), although, unlike at 4 months, this
was not statistically significant (p = 0.25 using chi-squared
test with continuity correction).
Using the mixed model approach, the mean difference
at 1 year for GFS was almost unchanged (−0.28 (−0.58,
0.02), p = 0.07), for fatigue self-efficacy was slightly higher (n=164)    
 centre 
Allocated to CLP (n=80) 
Follow-up 3 (n=69/77*) 
*3 dropouts prior to follow-up 3  
(second condition diagnosed,  n=1; personal reasons, n=1 
‘too much on’, n=1) 
 
Did not return outcome measures (n = 8) 
  
Not meeting inclusion criteria (n=112) 
Declined participation (n=142) 
On trial waiting list when recruitment 
closed (n=34)  
Excluded
 Received allocated intervention (n=80)  
 Did not receive allocated intervention (n=0) 
 
 
 
 
 
 
 
Missing baseline assessments (n=2) 
s distributed (n=452) 
Table 1 Descriptive demographic and baseline
characteristics of participants
FMP (n = 84) CLP (n = 80)
Gender [n (%)]
▪ Female 61 (73%) 58 (73%)
▪ Male 23 (27%) 22 (28%)
Age (years)
Mean (S.D.) 48.0 (10.2) 50.1 (9.1)
Range 23-73 28-70
Ethnicity [n (%)]
▪ White English 68 (85%) 69 (92%)
▪ White British 7 (9%) 5 (7%)
▪ Other 5 (6%) 1 (1%)
▪ Not stated 4 5
Disease type (self-reported) [n (%)]
▪ Benign 4 (5%) 2 (3%)
▪ Relapsing-remitting 35 (43%) 40 (51%)
▪ Secondary progressive 16 (20%) 23 (29%)
▪ Primary progressive 5 (6%) 8 (10%)
▪ Participant states “Don’t know” 21 (26%) 5 (6%)
▪ Not stated 3 2
APDDS score (Adapted Patient
Determined Disease Steps) [n (%)]
▪ 3 or less (No limitations on walking) 18 (22%) 15 (19%)
▪ 4 or 5 (MS interferes with walking) 37 (46%) 42 (54%)
▪ 6 or more (At min., needs stick/
crutch to walk 100 m)
26 (32%) 21 (27%)
▪ Not stated 3 2
Level of education [n (%)]
Highest qualification achieved:
▪ No qualifications 8 (10%) 8 (10%)
▪ One or more GCSE (or equiv.) 36 (46%) 29 (38%)
▪ One or more A level (or equiv.) 10 (13%) 12 (16%)
▪ First degree (or equiv.) 16 (20%) 19 (25%)
▪ Higher degree/professional qualification 9 (11%) 8 (11%)
▪ Not stated 5 4
Employment status [n (%)]
▪ In full time employment
(>30 hours per week)
15 (18%) 11 (14%)
▪ In part-time employment
(≤30 hours per week)
11 (14%) 13 (17%)
▪ Self-employed 4 (5%) 4 (5%)
▪ Not in paid employment (unemployed,
in education, retired, looking after home)
51 (63%) 50 (64%)
▪ Not stated 3 2
Table 1 Descriptive demographic and baseline
characteristics of participants (Continued)
FMP (n = 84) CLP (n = 80)
Marital status [n (%)]
▪ Married/cohabiting 63 (78%) 54 (71%)
▪ Single 5 (6%) 7 (9%)
▪ Separated/divorced 9 (11%) 14 (18%)
▪ Widowed 4 (5%) 1 (1%)
▪ Not stated 3 4
Years since diagnosis [n (%)]
▪ <1 yr 2 (3%) 4 (5%)
▪ 1–5 yrs 32 (40%) 21 (27%)
▪ 6–10 yrs 13 (16%) 19 (24%)
▪ 11–15 yrs 21 (26%) 12 (15%)
▪ ≥16 yrs 12 (15%) 22 (28%)
▪ Not stated 4 2
Percentages rounded to nearest integer and, thus, might not sum exactly to 100%.
CLP, current local practice; FACETS, Fatigue: Applying Cognitive behavioural
and Energy effectiveness Techniques to lifeStyle; GCSE, General Certificate of
Secondary Education; MS, multiple sclerosis.
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(−3.90 (−8.08, 0.28), p = 0.07).
Adverse events
No adverse events, as defined in the protocol, were
reported.
Secondary outcomes
For the MSIS-29 physical subscale (p = 0.046, SES = −0.23)
and the vitality subscale of the SF-36 (p = 0.03, SES = 0.37)
there was a significant difference in favour of the FACETS
arm at 1 year. None of the other secondary outcomes was
statistically significant. Effect sizes and significance levels
were similar using the mixed model approach.
Discussion
The modest improvements in fatigue severity and fa-
tigue self-efficacy in the FACETS arm at 4 months
were largely maintained at 1 year. While attrition was
relatively low at one year there was a diminution of
sample size to 131 (the original sample size calcula-
tion requirement was n = 146). Statistical power would
have been reduced slightly to 80% (NQuery Advisor)
and while still a reasonable level of power this is
lower than that at follow-ups 1 and 2 and might ac-
count in part for the slightly larger p-values obtained at
the 1 year follow-up.
In addition to improvements in fatigue severity and
self-efficacy there were improvements in MS-specific
quality of life that had not been present at 4 months
Table 2 Descriptive statistics and treatment effects at 1 year follow-up
Primary outcome measures Baseline (n = 159) Follow-up 1 (n = 146) Follow-up 2 (n = 144) Follow-up 3 (n = 131)
Global fatigue severity (GFS) subscale of the FAI (potential range 1 to 7, high scores indicate more fatigue)
FACETS mean (SD) 5.60 (0.98) 5.48 (0.92) 5.26 (1.03) 5.32 (1.00)
CLP mean (SD) 5.61 (1.09) 5.55 (1.17) 5.66 (0.93) 5.70 (1.01)
Mean difference in change from baseline [95% CI] - −0.03 (−0.33 to 0.28) −0.36 (−0.63 to −0.08) −0.30 (−0.61 to 0.01)
p value - 0.86 0.01 0.06
Std effect size - −0.03 −0.35 −0.29
Multiple Sclerosis Impact Scale-29 (MSIS-29) (potential range 0 to 100, high scores indicate more impact)
FACETS mean (SD) 49.6 (19.1) 47.3 (18.2) 44.9 (19.2) 46.2 (19.1)
CLP mean (SD) 43.9 (17.6) 42.2 (18.4) 43.0 (17.3) 47.2 (17.4)
Mean difference in change from baseline [95% CI] - 1.44 (−2.36 to 5.24) −1.56 (−6.45 to 3.34) −4.34 (−8.61 to −0.08)
p value - 0.46 0.53 0.046
Std effect size - 0.08 −0.08 −0.24
MS Fatigue Self-Efficacy scale (MS-FSE) (potential range 10 to 100, high scores indicate more certainty in controlling fatigue
FACETS mean (SD) 45 (17) 57 (17) 56 (19) 56 (16)
CLP mean (SD) 49 (16) 50 (17) 53 (17) 52 (17)
Mean difference in change from baseline [95% CI] - 9 (4 to 14) 6 (0 to 12) 6 (−1 to 12)
p value - 0.001 0.048 0.09
Std effect size - 0.54 0.36 0.34
Statistically significant secondary outcome measures
Vitality subscale of the SF-36 (potential range 0 to 100, high scores indicate higher quality of life)
FACETS mean (SD) 32.0 (16.8) 35.6 (19.4) 37.4 (20.3) 37.70 (18.75)
CLP mean (SD) 35.1 (19.7) 33.4 (16.8) 34.4 (17.30 32.43 (17.69)
Mean difference in change from baseline [95% CI] - 4.42 (−1.22 to 10.06) 6.38 (0.45 to 12.32) 6.64 (0.84 to 12.44)
p value - 0.12 0.04 0.03
Std effect size - 0.24 0.35 0.37
Multiple Sclerosis Impact Scale-29 (MSIS-29) - Physical subscale (potential range 0 to100, high scores indicate more impact)
FACETS mean (SD) 51.4 (21.4) 48.8 (19.7) 47.0 (21.3) 47.4 (21.0)
CLP mean (SD) 46.6 (20.3) 44.9 (20.5) 46.5 (19.8) 50.5 (20.1)
Mean difference in change from baseline [95% CI] - 1.39 (−2.87 to 5.65) −0.81 (−5.91 to 4.28) −4.74 (−9.40 to −0.08)
p value - 0.52 0.75 0.046
Std effect size - 0.07 −0.04 −0.23
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might be because the changes to lifestyle encouraged by
the FACETS programme may take some time to imple-
ment effectively.
Only some of those who declined participation in the
FACETS trial provided reasons for doing so. When rea-
sons were provided, they were predominantly related to
lack of time or existing work, holiday or childcare com-
mitments. A small minority of individuals felt that a
group approach was not for them or did not wish to take
part in a research trial. However, we acknowledge it is
possible that there might have been a recruitment bias
towards those more amenable to a non-pharmacological
approach.Conclusions
FACETS appears to have long term benefits for people
with MS at an estimated cost of £453 per person. Often
trials of nonpharmacological interventions do not meas-
ure long term follow-up or effects do not persist beyond
the short term. Given the progressive nature of MS and
the debilitating nature of fatigue, our demonstration of
small to medium improvements at 1 year follow-up is
encouraging.
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